Program Status: Inactive / Discontinued
Reason: Registry status: TERMINATED
Stage at discontinuation: phase_1
Development Phase
Discontinued / Inactive
Primary Status
Platform Technology
mRNA
Biologic Architecture
Target Indication
Neoplasms
Pathogen / Antigen
Last Verified
2026-07-10
Tier 1 Multi-Source Checked
Multi-Jurisdiction Regulatory Status
Official licensing, rolling submissions, or authorization status tracked across major health authorities.
| Regulatory Authority | Status & Details |
|---|---|
| US FDA | Not Filed / Pre-submission |
| EMA (Europe) | Not Filed / Pre-submission |
| Health Canada | Not Filed / Pre-submission |
| TGA (Australia) | Not Filed / Pre-submission |
Scientific Profile & Documentation
- Platform Architecture
- mRNA
- Lead Developer
- Merck Sharp & Dohme LLC
- Next Expected Milestone
- Primary completion (most advanced trial): 2022-08-25 (registry estimate)
- Analyst & Development Notes
- Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.
- Primary Source Documentation
- ClinicalTrials.gov NCT03948763 →
Registered Clinical Trials & Studies
Direct registry links to active, completed, or pivotal registration studies across phases.
NCT03948763
Discontinued / Inactive
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
Status: Active / Ongoing • Expected Readout: 2022-08-25
Milestone Overview
-
Stage VerificationDiscontinued / Inactive confirmed as of 2026-07-10.
-
Target MilestonePrimary completion (most advanced trial): 2022-08-25 (registry estimate)
Vaccine Data Navigator Candidate Profile Registry:
This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.